Novel therapeutic agents in clinical development for systemic lupus erythematosus. - Test2 - elhamkhani - TriplyDB

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34704902

about

FCGR3B copy number loss rather than gain is a risk factor for systemic lupus erythematous and lupus nephritis: a meta-analysis.Systemic lupus erythematosus 2014.An update on diet and nutritional factors in systemic lupus erythematosus management.Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy B Cell Modulation Strategies in Autoimmune Diseases: New Concepts.

P2860

Q38199779-B82923DD-E1BA-4EC8-A6E4-3173B1761978 Q38690108-91BE3BC8-A4B9-4968-B4A7-96C1543D02BD Q39178961-187303EF-71C9-4EED-8935-1A420F9D81EB Q42374807-43C03071-71D6-49B2-8861-D13CCC817CCC Q54980047-777B9E14-0EAA-4A94-B3A4-D6449133FA08

P2860

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34704902

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@ast

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@en

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@nl

type

label

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@ast

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@en

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@nl

prefLabel

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@ast

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@en

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@nl

P1433

Q34704902-F55E246D-9DB4-4C53-B640-DCD1C900A9D7

P1476

Q34704902-2182743D-9C63-4ADD-A5D1-EE5010A7B5F8

P2093

Q34704902-0D590A6B-ABC0-4C67-8C55-105EFAF1ADDF

Q34704902-6BB59871-713A-494C-BABC-B934306AEB80

Q34704902-811150F2-9DE6-4070-9C06-D7DA64E870FC

P275

Q34704902-F2BAF38E-9B22-4124-ACD1-6E049FE43B72

P2860

Q34704902-02243A95-7B4C-45E9-8601-F87890727BD8

Q34704902-04F06E96-AB8D-481E-B0C7-B647AE1E8010

Q34704902-1B25B376-43CF-4327-9F25-EE4B1FB2EE6B

Q34704902-1EC463C6-863E-4944-93D3-1EBFEF490D74

Q34704902-20897EAA-B517-410A-BB27-2B51C09FC4DF

Q34704902-287C1F69-B214-4791-A8FA-E5349085EE61

Q34704902-2AD0AFED-5920-4DC5-A6E1-FE476AE4D785

Q34704902-38916033-F1C8-4230-BA79-BC5A95D3B11D

Q34704902-3A97E1F5-416E-45C9-877D-909BE7796DC4

Q34704902-403FF3CB-965C-47FB-B4BE-9C304CB6CCF3

P2888

Q34704902-D7E24F37-C0C6-4049-B191-4D29A59E8AC6

P304

Q34704902-28510B9B-5DA7-4A93-A6BB-B2B22E656C18

P31

Q34704902-11771FEA-AA5A-4EED-83C1-300B17FBEB58

Q34704902-41F3F7F5-403E-41EA-97BB-12EEC6CFE2DA

P356

Q34704902-87794F8A-9030-4064-AFCE-8853FFF39FDF

P407

Q34704902-E39FF0B4-F9F7-463D-9E87-35B074FA4A68

P478

Q34704902-2FA2D698-8BC4-4B93-82A7-8575EFC4AD92

P5008

Q34704902-90E017DA-F8EB-4F41-AAD1-85BC1B86E7BC

P577

Q34704902-09D9BFF7-96C8-4D91-8A92-D4739FFF3156

P5875

Q34704902-F55436F0-2743-4A95-8600-DF983C05F346

P6179

Q34704902-C6F0F60C-F3D6-4397-8D83-A18D6181D13A

P698

Q34704902-A1DD29D4-CA12-437C-B6CE-C87A2A1DF966

P921

Q34704902-C7996B66-A32D-4F3A-ABFF-7B821EF9CC9A

P932

Q34704902-A45A0A3D-B7D5-429F-9FA2-7B718F9B401F

P356

1741-7015-11-120

P1433

P1476

Novel therapeutic agents in clinical development for systemic lupus erythematosus.

@en

P2093

David P D'Cruz

http://www.w3.org/2001/XMLSchema#string

Natasha Jordan

http://www.w3.org/2001/XMLSchema#string

Pamela M K Lutalo

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

Microarray analysis of gene expression in lupus

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

A new member of the immunoglobulin superfamily--CTLA-4

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

Treatment of systemic lupus erythematosus with epratuzumab.

Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections.

P2888

1741-7015-11-120

P304

120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1741-7015-11-120

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236636120

http://www.w3.org/2001/XMLSchema#string

P6179

1036318853

http://www.w3.org/2001/XMLSchema#string

P698

23642011

http://www.w3.org/2001/XMLSchema#string

P921

systemic lupus erythematosus

P932

3667088

http://www.w3.org/2001/XMLSchema#string